NYSE - Delayed Quote • USD
ADC Therapeutics SA (ADCT)
At close: 4:00 PM EDT
After hours: 4:15 PM EDT
Earnings Estimate
CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
No. of Analysts | 6 | 6 | 6 | 5 |
Avg. Estimate | -0.56 | -0.55 | -2.15 | -1.78 |
Low Estimate | -0.66 | -0.65 | -2.53 | -2.2 |
High Estimate | -0.48 | -0.45 | -1.72 | -1.51 |
Year Ago EPS | -0.74 | -0.58 | -2.94 | -2.15 |
Revenue Estimate
CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
No. of Analysts | 5 | 5 | 6 | 5 |
Avg. Estimate | 18.21M | 19.54M | 80.95M | 94.25M |
Low Estimate | 17.6M | 18.2M | 75.1M | 75.9M |
High Estimate | 18.85M | 20.7M | 92M | 108M |
Year Ago Sales | 18.99M | 41.55M | 69.56M | 80.95M |
Sales Growth (year/est) | -4.10% | -53.00% | 16.40% | 16.40% |
Earnings History
CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
---|---|---|---|---|
EPS Est. | -0.67 | -0.46 | -0.63 | -0.5 |
EPS Actual | -0.74 | -0.58 | -0.58 | -1.03 |
Difference | -0.07 | -0.12 | 0.05 | -0.53 |
Surprise % | -10.40% | -26.10% | 7.90% | -106.00% |
EPS Trend
CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
Current Estimate | -0.56 | -0.55 | -2.15 | -1.78 |
7 Days Ago | -0.56 | -0.55 | -2.15 | -1.78 |
30 Days Ago | -0.54 | -0.53 | -2.08 | -1.71 |
60 Days Ago | -0.47 | -0.46 | -1.92 | -1.61 |
90 Days Ago | -0.49 | -0.42 | -1.76 | -1.47 |
EPS Revisions
CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
Up Last 7 Days | 1 | -- | 1 | -- |
Up Last 30 Days | 1 | 1 | 2 | 1 |
Down Last 7 Days | -- | -- | -- | -- |
Down Last 30 Days | 1 | 1 | 1 | -- |
Growth Estimates
CURRENCY IN USD | ADCT | Industry | Sector | S&P 500 |
---|---|---|---|---|
Current Qtr. | 24.30% | -- | -- | 2.60% |
Next Qtr. | 5.20% | -- | -- | 13.40% |
Current Year | 26.90% | -- | -- | 5.20% |
Next Year | 17.20% | -- | -- | 13.30% |
Next 5 Years (per annum) | 15.80% | -- | -- | 11.11% |
Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
Reiterates | HC Wainwright & Co.: Buy to Buy | 4/15/2024 |
Reiterates | Guggenheim: Buy | 4/5/2024 |
Initiated | Guggenheim: Buy | 3/28/2024 |
Reiterates | RBC Capital: Outperform to Outperform | 3/14/2024 |
Reiterates | HC Wainwright & Co.: Buy to Buy | 3/6/2024 |
Maintains | RBC Capital: Outperform to Outperform | 2/26/2024 |
Related Tickers
STRO Sutro Biopharma, Inc.
3.4200
-1.44%
MRSN Mersana Therapeutics, Inc.
2.8500
-1.04%
ADAP Adaptimmune Therapeutics plc
1.0600
-1.85%
KPTI Karyopharm Therapeutics Inc.
1.0600
-2.75%
BDTX Black Diamond Therapeutics, Inc.
5.11
+0.99%
PSTX Poseida Therapeutics, Inc.
2.0500
-0.97%
RVMD Revolution Medicines, Inc.
35.33
-0.73%
ARQT Arcutis Biotherapeutics, Inc.
8.59
-1.83%
KURA Kura Oncology, Inc.
19.00
+1.33%
YMAB Y-mAbs Therapeutics, Inc.
14.84
-2.94%